65,437 trials
Breast Cancer · Metastases
Primary: Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) — 5.85; 4.17 Months — p=.0003
Hypercholesterolemia
Primary: Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End — 67.4; 36.3; 17.4 Percent — p=<0.001
Cancer · Breast Cancer
Primary: Overall Survival (OS) — 16.39; 15.64 months — p=.1162
Hepatitis B · Hepatitis A
Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value — 113; 100; 105; 92 subjects
Alcohol Dependence
Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03
Dyslipidemia
Primary: LDL Cholesterol — 159.7; 157.8 mg/dl
Colposcopy · Biopsy
Primary: Cell Collection Efficacy — 174; 170; 33; 14 Participants
Acute Bacterial Conjunctivitis
Primary: Clinical Resolution — 167; 147 Participants
Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants
Ankylosing Spondylitis
Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20. — 34; 37 patients — p=0.6031
Multiple Sclerosis
Primary: Number of Participants With Anti-Natalizumab Antibody Negative, Transient Positive, and Persistent Positive Status — 96; 3; 9 participants
Infection
Primary: Local Catheter Site Infection (LCSI) — 50; 70 Events — p=0.082
Drooling
Primary: Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injection — -2.1; -3.3; -3.5; -1.3 points on a scale
Acute Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants
Chronic Kidney Disease, Stage 5
Primary: Change From Baseline in Serum Phosphorus Levels at 4 Weeks — -1.73; -1.44 mg/dL — p=0.1130